Hyaluronic Acid-Based Hybrid Nanoparticles as Promising Carriers for the Intranasal Administration of Dimethyl Fumarate DOI Creative Commons
Carla Serri, M. Piccioni, Vincenzo Guarino

et al.

International Journal of Nanomedicine, Journal Year: 2025, Volume and Issue: Volume 20, P. 71 - 89

Published: Jan. 1, 2025

Dimethyl fumarate (DMF), the first-line oral therapy for relapsing-remitting multiple sclerosis, is rapidly metabolized into monomethyl fumarate. The DMF administration provokes gastrointestinal discomfort causing treatment withdrawal. present study aimed to develop an innovative formulation nasal administration. Lipid-polymer hybrid nanoparticles (LPNs) were developed improve stability, limiting side effects and increasing brain bioavailability by nose-to-brain targeting application. DMF-loaded unloaded LPNs with or without hyaluronic acid (HA) prepared using nanoprecipitation via magnetic/mechanical stirring technique. Particle morphology surface properties evaluated; drug content, viscosity, mucoadhesion determined. Physico-chemical stability of in was also explored. In vitro permeation experiments performed utilizing PermeaPad average sizes 120-250 nm a negative zeta potential -17.3 -43 mV obtained, primarily influenced presence HA. HA assured up 60 days promoting compared free-DMF. greatly improved viscosity mucoadhesive properties. did not exhibit any cytotoxicity showed rapid cell uptake starting from 15 min 2 h best internalization after 1 both epithelial neuronal lines. Nasal allowed quantify about 12 μg/mL rat cerebrospinal fluid. results highlight role improving performance as carrier particular, appear able enter neurons monolayers cells, allowing promote delivery.

Language: Английский

On a highway to the brain: A review on nose-to-brain drug delivery using nanoparticles DOI
María Lina Formica, Daniel Andrés Real, Matías L. Picchio

et al.

Applied Materials Today, Journal Year: 2022, Volume and Issue: 29, P. 101631 - 101631

Published: Sept. 5, 2022

Language: Английский

Citations

154
Chitosan: An overview of biological activities, derivatives, properties, and current advancements in biomedical applications DOI
Great Iruoghene Edo, Emad͏͏͏͏͏͏͏͏͏͏͏͏͏͏͏͏͏͏͏ Yousif, Mohammed H. Al‐Mashhadani

et al.

Carbohydrate Research, Journal Year: 2024, Volume and Issue: 542, P. 109199 - 109199

Published: June 27, 2024

Language: Английский

Citations

39
Intranasal drug delivery: The interaction between nanoparticles and the nose-to-brain pathway DOI
Yaoxing Chen,

Chenyun Zhang,

Yukun Huang

et al.

Advanced Drug Delivery Reviews, Journal Year: 2024, Volume and Issue: 207, P. 115196 - 115196

Published: Feb. 7, 2024

Language: Английский

Citations

38
Nasal Delivery to the Brain: Harnessing Nanoparticles for Effective Drug Transport DOI Creative Commons
Shivani Gandhi, Divyesh H. Shastri, Jigar Shah

et al.

Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(4), P. 481 - 481

Published: April 1, 2024

The nose-to-brain drug-delivery system has emerged as a promising strategy to overcome the challenges associated with conventional drug administration for central nervous disorders. This emerging field is driven by anatomical advantages of nasal route, enabling direct transport drugs from cavity brain, thereby circumventing blood–brain barrier. review highlights significance features cavity, emphasizing its high permeability and rich blood supply that facilitate rapid absorption onset action, rendering it domain neurological therapeutics. Exploring recent developments innovations in different nanocarriers such liposomes, polymeric nanoparticles, solid lipid dendrimers, micelles, nanoemulsions, nanosuspensions, carbon nanotubes, mesoporous silica nanogels unveils their diverse functions improving efficiency targeting specificity within this system. To minimize potential risk nanoparticle-induced toxicity mucosa, article also delves into latest advancements formulation strategies commonly involving surface modifications, incorporating cutting-edge materials, adjustment particle properties, development novel formulations improve stability, release kinetics, specificity. These approaches aim enhance while minimizing adverse effects. hold catalyze advancement safer more efficient systems, consequently revolutionizing treatments provides valuable resource researchers, clinicians, pharmaceutical-industry professionals seeking advance effective safe therapies

Language: Английский

Citations

21
Using the Intranasal Route to Administer Drugs to Treat Neurological and Psychiatric Illnesses: Rationale, Successes, and Future Needs DOI Open Access
Andrew Lofts, Fahed Abu-Hijleh,

Nicolette Rigg

et al.

CNS Drugs, Journal Year: 2022, Volume and Issue: 36(7), P. 739 - 770

Published: June 27, 2022

Language: Английский

Citations

51
PLGA nanoparticles for nasal drug delivery DOI Creative Commons

Salah Alghareeb,

Kofi Asare‐Addo, Barbara R. Conway

et al.

Journal of Drug Delivery Science and Technology, Journal Year: 2024, Volume and Issue: 95, P. 105564 - 105564

Published: March 12, 2024

The nasal route has routinely been used in the local delivery of drugs, however with innovations nanotechnology, there increased interest exploring this more for systemic, and brain/CNS delivery. This is because safe, non-invasive, medications can be self-administered to achieve rapid therapeutic drug levels minimal doses. Polymeric nanoparticles (NPs) such as PLGA NPs have a wide range applications delivery, due their large surface area modification targeting ligands polymers which enhances cellular uptake, bioavailability at target sites. review covers recent research on use small molecule drugs macromolecules via route. It some background information about challenges delivering most common polymer coatings are highlighted. Finally, patents clinical trials also covered.

Language: Английский

Citations

11
Nanoparticle-Based Drug Delivery Systems in Inhaled Therapy: Improving Respiratory Medicine DOI Creative Commons
Elena Cojocaru,

Ovidiu Rusalim Petriș,

Cristian Cojocaru

et al.

Pharmaceuticals, Journal Year: 2024, Volume and Issue: 17(8), P. 1059 - 1059

Published: Aug. 12, 2024

Inhaled nanoparticle (NP) therapy poses intricate challenges in clinical and pharmacodynamic realms. Recent strides have revolutionized NP technology by enabling the incorporation of diverse molecules, thus circumventing systemic clearance mechanisms enhancing drug effectiveness while mitigating side effects. Despite established success delivery oncology other disciplines, exploration inhaled therapies remains relatively nascent. NPs loaded with bronchodilators or anti-inflammatory agents exhibit promising potential for precise distribution throughout bronchial tree, offering targeted treatment respiratory diseases. This article conducts a comprehensive review applications medicine, highlighting their merits, ranging from heightened stability to exacting lung-specific delivery. It also explores cutting-edge technologies optimizing NP-loaded aerosol systems, complemented insights gleaned trials. Furthermore, examines current future prospects NP-based therapies. By synthesizing data perspectives, underscores transformative promise NP-mediated addressing chronic conditions such as obstructive pulmonary disease, pressing global health concern ranked third mortality rates. overview illuminates evolving landscape inhalation therapies, presenting optimistic avenues advancing medicine improving patient outcomes.

Language: Английский

Citations

11
A review of DNA nanoparticles-encapsulated drug/gene/protein for advanced controlled drug release: Current status and future perspective over emerging therapy approaches DOI

Ghazal Kadkhodaie Kashani,

Seyed Morteza Naghib, Sina Soleymani

et al.

International Journal of Biological Macromolecules, Journal Year: 2024, Volume and Issue: 268, P. 131694 - 131694

Published: April 18, 2024

Language: Английский

Citations

9
Polysaccharides: New Frontiers for Nasal Administration of Medicines DOI Creative Commons
Adryana Clementino,

Giulia Climani,

Annalisa Bianchera

et al.

Polysaccharides, Journal Year: 2025, Volume and Issue: 6(1), P. 6 - 6

Published: Jan. 15, 2025

The nasal cavity has become a focal point for drug delivery research. Beyond its use in treating local diseases, the route is appealing due ability to deliver systemically potent drugs with low oral bioavailability. Recent interest vaccination driven significant pre-clinical and clinical advancements. Further R&D holds promise expanding medications, offering innovative healthcare solutions. This review explores strategies using polysaccharides enhance of hydrophilic drugs, peptides, proteins, genes, other active compounds that typically struggle permeate epithelium. Polysaccharides are attractive excipients their potential absorption, regulate release, extend residence time through bioadhesive properties. Studies on mechanisms affecting toxicities, applications will also be reviewed considering particularities epithelium anatomy physiology. Most products these evaluation, but PecFent, pectin-based formulation, approved administration opioids breakthrough cancer pain, faster pain relief better benefit–risk ratio pectin. Other like chitosan, cyclodextrins, hyaluronic acid, alginate have shown enhancing absorption. approach transport from CNS (nose-to-brain), potentially advancing treatments neurodegenerative diseases.

Language: Английский

Citations

1
Development and Characterization of In Situ Gelling Nasal Cilostazol Spanlastics DOI Creative Commons
Maryana Salamah, Mária Budai-Szűcs, Bence Sipos

et al.

Gels, Journal Year: 2025, Volume and Issue: 11(2), P. 82 - 82

Published: Jan. 22, 2025

Cilostazol (CIL), a BCS class II antiplatelet aggregation and vasodilator agent, is used for cerebrovascular diseases to minimize blood–brain barrier dysfunction, white matter-lesion formation, motor deficits. The current work aimed develop optimize cilostazol-loaded spanlastics (CIL-SPA) nose-to-brain delivery overcome the low solubility absorption, first pass-metabolism, adverse effects. optimal CIL-SPA formulation was loaded into Phytagel® (SPA-PG), Poloxamer-407 (SPA-P407), chitosan (SPA-CS) gel bases characterized in terms of colloidal properties, encapsulation efficiency (EE%), mucoadhesive biopharmaceutical aspects. developed situ gelling formulations showed <300 nm average hydrodynamic diameter, <0.5 polydispersity index, >|±30| mV zeta potential with high EE% (>99%). All met droplet size-distribution criteria nasal requirements (<200 µm), all adequate mucoadhesion properties. Both BBB-PAMPA horizontal permeability study through an artificial membrane revealed that had higher CIL flux cumulative at vitro conditions compared initial CIL. drug-release released ca. 100% after 2 h. Therefore, could be promising improving bioavailability delivery.

Language: Английский

Citations

1